A group of researchers investigated single-molecule electrical detection of ribonucleic acid (RNA) cancer biomarkers.
ReCode raises another $50M; Histogen halts clinical development; 60 Degrees withdraws Covid-19 IND
ReCode Therapeutics is back with an additional $50 million more than a year after it raised a $120 million Series B. The Menlo Park, CA-based